-
Featured Press Release
Aspira Women’s Health Reports Second Quarter 2021 Financial Results
Learn More -
Press Release
Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines
Learn More -
Press Release
Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021
Learn More
Recent News
Choose a Category:
-
Aspira Women’s Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer
Press Release
Signals Call to Action for Immediate Progress in Conquering Ovarian Cancer For a PDF version of this press release, click here. Austin, TX – September 9, 2021: Heralding the beginning of Ovarian Cancer Awareness Month, Aspira Women’s Health, Inc (“Aspira”) (Nasdaq: AWH) will ring the closing bell at NASDAQ on Thursday, September 9, 2021 to…
-
Aspira Women’s Health Reports Second Quarter 2021 Financial Results
Press Release
For a PDF of this press release, including balance sheets click here. Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 AccessionsNew Publication Demonstrates OVA1 Superiority to Standard of CareExpanded Access of OVA1 Through AIM Specialty Health Conference call scheduled for today, August 12 at 4:30 p.m. ET AUSTIN, Texas — August…
-
Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12
Press Release
Conference Call scheduled for Thursday, August 12th at 4:30 p.m. ET For a pdf of this press release please click here AUSTIN, Texas — July 27, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the second quarter ended June 30, 2021 on…
-
Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines
Press Release
AIM is a member of the Anthem Blue Cross Blue Shield family of companies which promotes optimal care through use of evidence-based clinical guidelines and real-time decision support for both providers and their patients. AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C. and US…
-
Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021
Press Release
For a PDF version of this press release, click here. Data demonstrates the performance of OVASight in a low prevalence population-89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6%for the management of suspected Benign Pelvic Masses AUSTIN, Texas; June 3, 2021 – Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on…